Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Ovarian Carcinoma: early-phase trial registry
22 of 36 indexed Ovarian Carcinoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #419 of 28,707 conditions by registered trial count.
36 US clinical trials · 22 currently recruiting · #419 of 28,707 conditions by registered trial count
Ovarian Carcinoma: 36 US clinical trials tracked, 22 recruiting.
Ovarian Carcinoma is the subject of 36 registered US clinical trials on ClinicalTrials.gov, 22 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 16 in Phase 1-2 (earlier-stage). The most active sponsor is M.D. Anderson Cancer Center, running 6 of these trials.
Enrollment posture brief
Registry condition ovarian-carcinoma
OPEN 22 | RECR 61% | LATE 2 | EARLY 16 | RANK #419 | SPON 6
Volume-matched condition peers
Nearest open-share peer: Breast Cancer Metastatic (61% recruiting · 18 trials)
Ovarian Carcinoma lists 22 open slots (61% of 36 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Ovarian Carcinoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Ovarian Carcinoma is recruiting above its size-band peers.
22 of 36 indexed trials (61.1%) are open to enrollment, against a 39.7% average across 762 conditions with 20-99 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Ovarian Carcinoma research.
M.D. Anderson Cancer Center accounts for 6 of 36 trials (16.7%). 20 distinct sponsors appear on at least one study for this condition label.
-
Typical Ovarian Carcinoma enrolment sits around 86 participants.
Median target enrolment is 86 among the 36 trials that report a genuine target (sentinel values excluded). 19 of those (52.8%) plan for fewer than 100 participants.
-
Ovarian Carcinoma research is mostly interventional.
34 interventional and 2 observational studies make up this index (94.4% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
36 total, page 1 of 1
The Vanguard Study: Testing a New Way to Screen for Cancer
National Cancer Institute (NCI)
NCT06995898
Clonal Hematopoiesis and Therapy-Emergent Myeloid Neoplasms in Patients With Cancers, CHANCES Study
University of Washington
NCT06295965
Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors
M.D. Anderson Cancer Center
NCT00488878
A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer
NRG Oncology
NCT04251052
Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer
NRG Oncology
NCT06580314
Access to Genetic Testing in Underserved Patients With Cancer
University of Southern California
NCT06422455
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
NCT06172478
A Study of Intra-operative Imaging in Women With Ovarian Cancer
Memorial Sloan Kettering Cancer Center
NCT04878094
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
M.D. Anderson Cancer Center
NCT03604315
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
Avacta Life Sciences
NCT04969835
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics
NCT06586957
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
Children's Oncology Group
NCT04851119
Pilot Randomized Controlled Trial of a Collaborative Agenda-setting Intervention (CASI) for Patients With Ovarian Cancer
Dana-Farber Cancer Institute
NCT06543537
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
Memorial Sloan Kettering Cancer Center
NCT06290193
Cryocompression With or Without Cilostazol for the Prevention of Paclitaxel-induced Neuropathy in Patients With Gynecological Cancers
Emory University
NCT06492070
Ultrasound Microvessel Imaging for the Evaluation of Ovarian and Adnexal Lesions
Mayo Clinic
NCT07280312
A Study Comparing Perioperative Stress Reduction vs. Standard of Care in Ovarian Cancer (PRESERVE)
Memorial Sloan Kettering Cancer Center
NCT05429970
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Dana-Farber Cancer Institute
NCT06677190
DT2216 + Paclitaxel in Platinum-Resistant Ovarian Cancer
Elizabeth Stover, MD, PhD
NCT06964009
Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
Dana-Farber Cancer Institute
NCT04997096
Adapted Helping Ovarian Cancer Patients Cope Intervention to Address Burnout for Gynecologic Oncology Clinicians
Fred Hutchinson Cancer Center
NCT07282158
Intraperitoneal Cytokine-Induced Memory Like (CIML) Natural Killer (NK) Cells in Recurrent Ovarian Cancer
Dana-Farber Cancer Institute
NCT06321484
Screening for Ovarian Cancer in Older Patients (PLCO Screening Trial)
National Cancer Institute (NCI)
NCT01696994
HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics
City of Hope Medical Center
NCT04905082
Energy Balance Interventions in Increasing Physical Activity in Breast Cancer Gene Positive Patients, Lynch Syndrome-Positive Patients, CLL Survivors or High-Risk Family Members
M.D. Anderson Cancer Center
NCT02194387
Prophylactic Salpingectomy With Delayed Oophorectomy
M.D. Anderson Cancer Center
NCT01907789
Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer
National Cancer Institute (NCI)
NCT02345265
HOT: HIPEC in Ovarian Cancer as Initial Treatment
Mercy Medical Center
NCT02124421
Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
Jonsson Comprehensive Cancer Center
NCT04147494
Dietary Magnesium in Preventing Low Blood Magnesium Levels in Patients With Ovarian Cancer Receiving Carboplatin Chemotherapy
M.D. Anderson Cancer Center
NCT04310826
PET/MR Versus CECT Scans in Imaging Patients With Ovarian Cancer or Highly Suspected Ovarian Cancer
M.D. Anderson Cancer Center
NCT03965481
A Study of Sacituzumab Govitecan (IMMU-132) in Platinum-resistant Ovarian Cancer Patients
Yale University
NCT06028932
Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer
NRG Oncology
NCT03180294
Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
NCT02159989
EHealth Mindful Movement and Breathing in Improving Outcomes in Participants Undergoing Gynecologic Surgery
Wake Forest University Health Sciences
NCT03379376
Clinical Outcomes for Offering Genetic Testing in a Tiered Approach
Fred Hutchinson Cancer Center
NCT04902144
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 8 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Ovarian Carcinoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Ovarian Carcinoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Ovarian Carcinoma page
36 registered trials, 22 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 22 Ovarian Carcinoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- M.D. Anderson Cancer Center sponsors the most Ovarian Carcinoma trials on record, review their full trial history before evaluating a specific study. See M.D. Anderson Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Ovarian Carcinoma condition card totals 36 registered trials; most-linked intervention Biospecimen Collection; top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.